Our representative will contact you shortly!

AstraZeneca Pharmaceuticals; AstraZeneca today announced that it has entered into an agreement with Perrigo Company plc for the divestment of US rights to Entocort® (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn’s disease, an area of medicine outside AstraZeneca’s strategic focus.

As AstraZeneca will no longer retain an interest in the US rights to , the upfront gross receipt will be reported in Other Operating Income in the Company’s financial statements.

No: INP000002213, IA SEBI Regn.

), you need not undergo the same process again when you approach another intermediary." The transaction does not include the transfer of any AstraZeneca employees or facilities.Luke Miels, Executive Vice President, Global Product and Portfolio Strategy, AstraZeneca, said: “Our agreement with Perrigo completes the global divestment of , emphasising our strategic focus on three main therapy areas and providing further simplification of our supply chain. Raymond Silcock. For more information, read the "Cookie Policy" under This website uses information gathering tools such as cookies and other similar technologies. Svend Andersen. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others. Expert panelists review the causes, diagnostic work-up, management, and emerging therapies inherent in the evolving paradigm of irritable bowel syndrome.AstraZeneca Enters into Agreement with Perrigo for Rights to Entocort in the USAstraZeneca Enters into Agreement with Perrigo for Rights to Entocort in the USAstraZeneca has entered into an agreement with Perrigo for the divestment of US rights to Entocort, a gastroenterology medicine for patients with mild to moderate Crohn's disease./news/astrazeneca-enters-into-agreement-with-perrigo-for-rights-to-entocort-in-the-usUnder the terms of the agreement, Perrigo will pay AstraZeneca $380 million upon completion of the transaction to acquire the rights to sell  capsules marketed by Par Pharmaceuticals. Talk with your doctor before getting any vaccines. AstraZeneca’s 2015 Core Earnings Per Share guidance was upgraded at Year-To-Date & Third Quarter 2015 Results on 5 November and is maintained as it was provided, in the range of mid to high single-digit percentage increase versus the prior year and at constant exchange rates. Executive Vice President and Chief Financial Officer.
…


The transaction is expected to complete by the end of 2015, subject to customary closing conditions. Use of some vaccines with Entocort EC (budesonide extended-release capsules (entocort EC)) may either raise the chance of an infection or make the vaccine not work as well. Temporary Password has been sent to registered number and email address.This website uses information gathering tools such as cookies and other similar technologies. Under the terms of the agreement, Perrigo will pay AstraZeneca $380 million upon completion …

For more information, read the "Cookie Policy" under

It is used to treat mild to moderate Crohn's disease, an inflammatory disease of the bowel. The full effect of this medication is usually seen within 2 to 4 weeks. If you do not consent, do not use this website.

Under the terms of the agreement, Perrigo will pay AstraZeneca …

By clicking 'Accept' on this banner or by using this website, you consent to the use of cookies unless you have disabled them.